Hemophilia is a genetic disorder in which patient’s blood do not clot normally due to lack of blood-clotting proteins. Hemophilia treatment mainly depends on its severity. The treatment includes timely replacement of the specific clotting factor. Increasing number of hemophilic patient requiring treatment and increased diagnosis rate for Hemophilia are major factors anticipated to drive market growth.
Grab Sample of this Report at: @
Market Dynamics
The major factors driving growth of the Hemophilia treatment market is increasing diagnosis rate. In the U.S., majority of Hemophilia cases are diagnosed at a very young age. According to CDC, the median age for diagnosis is one month for individuals with severe symptoms, 8 months for individuals with moderate Hemophilia, and 36 months for people with mild Hemophilia. Hemophilia treatment is more costly and less effective in 25% of individuals with severe type A disease and in the three percent of individuals with severe type B disease who produce neutralizing inhibitors against factor VIII and factor IX, respectively. Various ongoing treatments such as gene therapy can significantly improve the quality of life for Hemophilia patients by eradicating frequent hospital visits and infusions and shifting patients from severe to mild Hemophilia. Increasing R&D investments and product innovations by many industry players is expected to drive growth of the market over the forecast period. For instance, in 2016, FDA approved Bayer’s Kovaltry drug, a low-frequency dosage for Hemophilia A, which requires two to three doses per week.
Key features of the study:
This report provides in-depth analysis of Hemophilia treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global Hemophilia treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG, Pfizer, Inc., Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global Hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Hemophilia treatment market
Detailed Segmentation:
Global Hemophilia Treatment Market, By Product Type:
Recombinant coagulation factor
Plasma derived coagulation factor
Antifibrinolytic agents
Desmopressin
Global Hemophilia Treatment Market, By Disease Type:
Hemophilia A
Hemophilia B
Hemophilia C
Global Hemophilia Treatment Market, By Geography:
North America
By Product Type:
Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin
By Disease Type:
Hemophilia A
Hemophilia B
Hemophilia C
By Country:
U.S.
Canada
Latin America
By Product Type:
Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin
By Disease Type:
Hemophilia A
Hemophilia B
Hemophilia C
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin
By Disease Type:
Hemophilia A
Hemophilia B
Hemophilia C
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type:
Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin
By Disease Type:
Hemophilia A
Hemophilia B
Hemophilia C
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin
By Disease Type:
Hemophilia A
Hemophilia B
Hemophilia C
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Recombinant coagulation factor concentrates
Plasma derived coagulation factor concentrates
Antifibrinolytic agents
Desmopressin
By Disease Type:
Hemophilia A
Hemophilia B
Hemophilia C
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Baxalta *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Baxter International, Inc.
Biogen Idec, Inc.
Bayer AG
CSL Behring
Chugai Pharmaceutical Co.
Ferring B.V.
Genentech, Inc.
Hospira, Inc.
Kedrion
Novo Nordisk
Octapharma AG
Pfizer, Inc.
Sanofi SA
Shire Plc.
Swedish Orphan Biovitrum AB
Get Exclusive Discount at: @
“*” marked represents similar segmentation in other categories in the respective section.
Industry Forecast Research 